GoodRx(US:GDRX) ZACKSยท2024-08-06 14:20Group 1 - The upcoming report from GoodRx Holdings, Inc. (GDRX) is expected to show quarterly earnings of $0.09 per share, reflecting a 28.6% increase year over year [1] - Analysts forecast revenues of $200.68 million for the quarter, indicating a 5.8% year-over-year growth [1] - There has been no revision in the consensus EPS estimate for the quarter over the past 30 days, suggesting stability in analyst projections [1] Group 2 - Analysts estimate 'Revenue- Prescription transactions' at $146.29 million, representing a 7.2% increase from the previous year [4] - The consensus estimate for 'Revenue- Other' is $5.35 million, indicating a 9.2% increase from the prior-year quarter [4] - 'Revenue- Pharma Manufacturer Solutions' is projected to reach $27.48 million, reflecting a 13.1% increase year over year [4] Group 3 - The average prediction for 'Revenue- Subscription' is $21.17 million, which shows an 11.4% decrease compared to the year-ago quarter [5] - GoodRx shares have increased by 0.9% over the past month, contrasting with the Zacks S&P 500 composite's decline of 6.7% [5] - GDRX holds a Zacks Rank 3 (Hold), indicating it is expected to closely follow overall market performance in the near term [5]